Asthma Origins and Remission Study

Asthma Clinical Trial

— ARMS  

Official title:

A Better Understanding of Molecular Mechanisms Leading to Asthma and Its Remission

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03141814
• Other study ID #: NL2015001
• Status: Recruiting
• Phase: N/A
• First received: May 3, 2017
• Last updated: July 12, 2017
• Start date: October 2015
• Est. completion date: October 2018

Study information

• Verified date: July 2017
• Source: University Medical Center Groningen
• Contact: Maarten van den Berge, MD, PhD
• Phone: +31-50-3615260
• Email: m.van.den.berge[@]umcg.nl
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Asthma is characterized by chronic airway inflammation of the large and small airways. Asthma patients often have episodes with symptoms of dyspnea, wheezing and nocturnal awakening. Currently available inhaled anti-inflammatory treatments reduce the airway inflammation and treatment but do not cure the disease. Therefore asthma patients often need life-long treatment to control their asthma.

In a small subset of patients, their asthma resolves spontaneously. This phenomenon is called asthma remission. Subjects with asthma remission do not experience symptoms or signs of airway inflammation anymore and do not require inhaled treatments. Some subjects with asthma remission also have a completely normal lung function without signs of bronchial hyperresponsivess: they have complete asthma remission. Unfortunately, asthma remission occurs only in a small subset of 15-25% of asthma patients.Objective: to determine the underlying mechanisms and molecular events leading to remission of asthma.

Description:

Rationale: Asthma inception occurs only in susceptible individuals, and is often triggered by specific environmental factors, such as respiratory viruses and aeroallergens. Although asthma is generally viewed as a chronic persistent disease, remission of asthma is possible in a subset of patients. This is highly relevant, since understanding mechanisms that contribute to asthma inception and remission may teach us how asthma can be stopped and thus may provide novel avenues for the treatment of asthma. In adulthood, average remission rates of asthma are approximate 2% per year 1. We observed that remission in adulthood is more likely with earlier onset of asthma, less airway obstruction, more severe bronchial hyperresponsiveness, and smoking cessation. A proper definition of remission is very important; we therefore introduced the terms 'clinical remission' and 'complete remission' 2. Clinical remission was defined as the absence of asthma symptoms and no use of asthma medication, complete remission as the absence of asthma symptoms, no use of asthma medication, normal lung function and no bronchial hyperresponsiveness. In a longitudinal study of 119 allergic asthmatic children followed-up for 30 years, our group found that clinical remission occurred in 30% and complete remission in 22% of all cases.

Objective: to determine the underlying mechanisms and molecular events involved in the inception and remission of asthma.

Methods: We will include a 40 subjects divided over the following 4 groups: i) clinical asthma remission (10 subjects), ii) complete asthma remission (10 subjects), iii) ongoing asthma (10 patients), iv) non-asthmatic healthy controls (10 subjects) in a cross-sectional study. All subjects will be extensively clinically characterized including respiratory symptoms/questionnaires, in- and expiratory CT-scans, and parameters of large and small airway function and inflammation. In addition, blood and nasal epithelial brushes will be obtained to study the genetic and epigenetic mechanisms of asthma remission. Finally, bronchoscopy with bronchial biopsies and brushes will be performed under conscious sedation. Bronchial biopsies from all four patient groups will be used for index FACS sorting of the three most important cell types orchestrating the asthmatic inflammatory process: i.e. B lymphocytes, CD4+ T cells and CD8+ T cells. We will perform single cell whole-genome transcriptome sequencing on at least 100 cells of each type and the primary outcome of the study is to identify how the transcriptomic profile of bronchial epithelial cells is changed between asthma patients and healthy controls as a consequence of asthma inception and what transcriptomic profile changes occur in CD4+ CD8+ and B lymphocytes in the airways from subjects with asthma remission compared to patients with ongoing asthma and healthy controls.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: October 2018
• Est. primary completion date: October 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 65 Years

Eligibility

Inclusion criteria for all subjects:

• Age between 40 and 65 years old.

• Smoking history = 10 packyears.

Inclusion criteria for all asthmatics and asthma remission subjects:

• Development of asthma symptoms before 21 years.

Specific inclusion criteria for the 4 different groups:

• Group 1. Subjects with clinical asthma remission:

• Documented history of asthma diagnosed according to latest GINA guidelines, i.e. respiratory symptoms and either bronchodilator reversibility (improvement in FEV1 of more than 12% of baseline (and at least 200 mL) after inhalation of 800 µg salbutamol.

• No use of asthma medications such as inhaled or oral corticosteroids, ß2-agonists or anticholinergic in the last 3 years.

• No symptoms of wheeze or asthma attacks during the last 3 years.

• Group 2. Subjects with complete asthma remission

• Documented history of asthma diagnosed according to latest GINA guidelines, i.e. respiratory symptoms and either bronchodilator reversibility (improvement in FEV1 of more than 12% of baseline (and at least 200 mL) after inhalation of 800 µg salbutamol.

• No use of asthma medications such as inhaled or oral corticosteroids, ß2-agonists or anticholinergics in the last 3 years.

• No symptoms of wheeze or asthma attacks during the last 3 years.

• FEV1 > 90% predicted.

• Absence of bronchial hyperresponsiveness, i.e. both PC20 methacholine > 8 mg/ml and PC20 AMP > 320 mg/ml.

• Group 3. Patients with ongoing asthma

• Documented history of asthma diagnosed according to latest GINA guidelines, i.e. respiratory symptoms and either bronchodilator reversibility (improvement in FEV1 of more than 12% of baseline (and at least 200 mL) after inhalation of 800 µg salbutamol.

• Use of inhaled corticosteroids or either persistent symptoms of wheeze, cough, or dyspnea or regular use of ß2 agonists at least once a week during the last 2 months.

• PC20 methacholine < 8 mg/ml.

• Group 4. Non-asthmatic controls

• No history of asthma.

• No use of inhaled corticosteroids or ß2-agonists for a period longer than 1 month.

• No symptoms of wheeze, nocturnal dyspnea, or bronchial hyperresponsiveness.

• PC20 methacholine > 8 mg/ml, FEV1/FVC > 70% and FEV1 > 80% predicted.

Related Conditions & MeSH terms

• Asthma

Locations

Country	Name	City	State
Netherlands	UMCG	Groningen

Sponsors (2)

Lead Sponsor	Collaborator
University Medical Center Groningen	GlaxoSmithKline

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Single cell sequencing data	Single cell mRNA sequencing of lymphocytes in bronchial biopsies and blood eosinophils	baseline
Secondary	Spirometry	FEV1, FVC, FEV1/FVC, FEF25-75.	baseline
Secondary	body box	RV, RV/TLC, FRC, IC, ERV	baseline
Secondary	HRCT	emphysema and small airways disease	baseline
Secondary	Airway inflammation	Sputum, blood, biopsy inflammatory cell counts, exhaled nitric oxide, small particles in exhaled breath	baseline
Secondary	Small airways disease	Multiple breath nitrogen washout: LCI, Sacin, Scond	baseline
Secondary	genetic and genome-wide mRNA, non-coding RNA, and DNA methylation	assessed in bronchial and nasal epithelial brushes, biopsies and blood	baseline